BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190827
DTEND;VALUE=DATE:20190830
DTSTAMP:20260515T010533
CREATED:20180531T135859Z
LAST-MODIFIED:20190430T084109Z
UID:16049-1566864000-1567123199@www.pharmajournalist.com
SUMMARY:3rd Annual IPF Summit
DESCRIPTION:The IPF Summit focuses exclusively on closing the translational gap between preclinical predictability and clinical attrition to accelerate the development of truly curative idiopathic pulmonary fibrosis (IPF) therapeutics. \n \nWith the 2019 conference expanding upon an even greater breadth and depth of content\, you’ll hear three days of unrivalled scientifically driven and case-study based analysis and discussion\, as together leading academia and biopharma advance the IPF drug development frontier. \nLast year\, over 90 of IPF’s expert drug developers came together to advance the standardisation of imaging\, share clinical insights\, and evaluate better recapitulating disease physiology in vitro exclusively for IPF: \n“This was a superb meeting combining several emerging themes in IPF therapies and a dynamic mix of formal presentations with impromptu networking. All the speakers were excellent\, and every session provided novel and important insight regarding IPF. The effort the speakers put into their presentations was evident. Great job!” \nCeders-Sinai Medical Center \nWith the incredible breakthrough success of drugs now in our arsenal for slowing IPF disease progression\, the increasing importance of identifying genetic mechanisms\, closing the translational gap between preclinical and clinical results\, and developing candidates to reverse fibrosis have opened up further challenges within IPF drug development. \nJoin “part 3” as the IPF community converges again to: \n\nAnalyze the latest understanding of IPF pathology for improved target validation of next generation therapeutics and the potential to promote tissue regeneration to achieve reversal of fibrosis\nCritically discuss how to design the next generation of phase III clinical trials for candidate success in light of a current standard of care\nOutline progressions in the standardization of imaging and advancements of biomarkers to improve translational success and more confident diagnosis of patients\n\nTo learn more about 3rd Annual IPF Summit and to register online\, visit https://ter.li/i81anp \nContact \nEmail – info@hansonwade.com\nPhone – +1 415 735 3289
URL:https://www.pharmajournalist.com/event/ipf-summit/
LOCATION:Sheraton San Diego Hotel & Marina\, 1380 Harbor Island Drive\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR